Prescribing Trazodone

Why Trazodone Still Matters

Trazodone is one of the most-prescribed psychiatric medications in the United States, and almost nobody prescribes it for what the FDA approved it to do. Licensed in 1981 as an antidepressant, it long ago migrated into a second life as America's default off-label hypnotic: a cheap, non-scheduled, non-addictive sleeping pill that costs roughly three cents a dose. Marketing had nothing to do with that migration. The pharmacology explains it: at low doses trazodone is a potent H1 and 5-HT2A antagonist that produces sleep, and unlike benzodiazepines and z-drugs it improves sleep architecture rather than degrading it.

The drug's reputation suffers from two opposite distortions. Sleep specialists sometimes dismiss it because the randomized primary-insomnia database is thin (there was never a sponsor with an incentive to build one; it went generic decades ago). Meanwhile clinicians who reach for it reflexively at 50 mg qhs often forget that it is an antidepressant in its own right, with the side effects of one: orthostatic hypotension, next-day sedation, a rare but real risk of priapism, and an active metabolite (mCPP) that can cause trouble when the wrong CYP2D6 inhibitor is layered on top.

This guide covers both trazodones: the sedating adjunct used nightly for insomnia, and the full-dose antidepressant most clinicians have never titrated because they can't get patients past the sedation.

Part 1: Indications

FDA-Approved

• Major depressive disorder (the only on-label use)

Trazodone is rarely used at true antidepressant doses (300 to 400 mg/day), because the sedation that makes it an excellent hypnotic makes full-dose monotherapy hard to tolerate. Head-to-head meta-analyses rank it among the less efficacious and less acceptable antidepressants (higher dropout, largely from sedation), not because it doesn't work, but because patients quit before reaching an effective dose. Think of it as a second- or third-line antidepressant, worth a trial after the top two choices fail, particularly when insomnia, agitation, or a desire to avoid weight gain and sexual side effects dominates the picture.

The Evidence-Based Off-Label Uses

Primary and secondary insomnia: the real reason it's on your formulary. At 25 to 150 mg qhs it increases total sleep time by roughly 30 to 50 minutes, and it does so while increasing slow-wave (deep, stage 3) sleep rather than suppressing it the way benzodiazepines and z-drugs do. It works for initial, middle, and terminal insomnia. It is especially valuable for insomnia secondary to depression, where a low nightly dose can be layered onto an activating antidepressant (an SSRI or bupropion) to rescue sleep without adding a second full-dose drug.

Sleep disturbance in PTSD. Trazodone is used off-label for the sleep complaint, though the 2023 VA/DoD PTSD guideline does not recommend it; the evidence was rated insufficient to recommend for or against. Prazosin is the medication that guideline suggests for nightmares.

Behavioral and psychological symptoms of dementia (BPSD). Useful adjunctively for agitation and insomnia in dementia, with a signal for particular benefit in frontotemporal dementia. Typical dementia dosing runs around 50 to 100 mg/day (mean about 100 mg/day, range 50 to 300). It does not improve cognition or slow decline: a UK cohort (n≈2,199) found no MMSE benefit versus citalopram or mirtazapine. It does manage the behavioral symptoms with acceptable tolerability, and it avoids the mortality signal of antipsychotics in this population.

Antipsychotic-induced akathisia. As a 5-HT2A antagonist, trazodone 50 to 100 mg qhs reduced akathisia in a small placebo-controlled trial. It is a reasonable adjunct alongside propranolol and mirtazapine when a dose reduction or benzodiazepine isn't enough.

Generalized anxiety disorder. In the classic Rickels RCT (1993), trazodone (about 255 mg/day) beat placebo but underperformed imipramine. It is not a first-line anxiolytic, but the sedating profile can help anxious, insomniac patients.

Insomnia in TBI and schizophrenia. 50 to 200 mg qhs, after behavioral approaches, when a non-addictive sleep agent is wanted.

Where the Evidence Is Weak or Absent

• Panic disorder, OCD: little evidence; don't reach for trazodone here.
• SSRI-induced sexual dysfunction: the "add trazodone to reverse it" strategy rests on one tiny open-label trial and is likely placebo; don't rely on it.
• Neuroprotection / dementia prevention: mouse models hint at reversal of protein aggregation, but there is no human evidence that trazodone preserves cognition or reduces dementia incidence. Do not use it for that purpose.

Who Is a Good Candidate?

• Patients with insomnia, primary, or secondary to depression, PTSD, or dementia
• Patients you want to keep off scheduled hypnotics (history of substance use, older adults, anyone where dependence is a concern)
• Depressed patients where avoiding weight gain and sexual dysfunction is a priority
• Depressed patients already taking trazodone for sleep, in whom you can climb to an antidepressant dose rather than adding a second drug

Who Is a Poor Candidate?

• Patients at high risk of hypotensive falls (frail elderly, autonomic dysfunction, existing orthostasis)
• Patients with significant cardiac disease (orthostasis, QT)
• Depressed patients whose picture is dominated by fatigue and hypersomnia, where sedation works against you
• Men with a history of priapism, or patients with sickle cell / vaso-occlusive disease

Part 2: Workup and Candidacy

Trazodone requires far less pre-work than lithium. There are no mandatory baseline labs and no serum-level monitoring. What you owe every patient is a short, targeted history and, in selected patients, an ECG.

At Baseline

• Cardiac and orthostatic screen. Ask about known cardiac disease, syncope, dizziness on standing, and falls. Check a baseline blood pressure, ideally with orthostatics, especially in older or frail patients.
• Priapism risk in men. Ask briefly about erectile history and any prior prolonged or painful erections. A prior priapism episode is a relative contraindication.
• Medication reconciliation for interactions. Specifically scan for CYP3A4 inhibitors (which raise trazodone levels, driving sedation and QT effects) and CYP2D6 inhibitors (which raise mCPP, driving dysphoria and anxiety). See Part 7.

Consider a Baseline (and Periodic) ECG If:

• Age 65 or older
• Known cardiovascular disease or prior arrhythmia
• Co-prescribed a CYP3A4 inhibitor or another QT-prolonging drug (e.g., methadone, ziprasidone)
• Electrolyte abnormalities (low potassium or magnesium)
• Hepatic or renal impairment (reduced clearance, so higher levels)

Part 3: How to Start and Dose

The most important dosing rule is to give the whole dose at bedtime. Trazodone's short half-life (about 7 to 8 hours) is long enough to carry a patient through the night and short enough that most of the sedation is spent by morning. Bedtime dosing dramatically improves tolerability compared with divided dosing, even with the standard instant-release tablet, and it is the reason full-dose divided antidepressant regimens fail so often.

Formulations

• Instant-release (generic): use this. Cheap (about $0.03/tablet), flexible, available in 50, 100, 150, and 300 mg. Scored tablets let you fine-tune.
• Extended-release (Oleptro): gone. The XR formulation was discontinued in 2015 and is no longer commercially available. It never delivered on its promise anyway: modest effect size (about 0.28), and daytime somnolence remained common (31% vs 16% placebo). Don't go looking for it.

For Insomnia (the Common Use)

• Start: 25 to 50 mg at bedtime.
• Titrate: increase toward 150 mg qhs over 7 to 10 days as needed for effect.
• Most insomnia patients respond at or below 150 mg qhs; many at 50 to 100 mg.

For Depression (the On-Label Use)

• Antidepressant efficacy generally requires 150 to 400 mg/day (label range extends to a maximum of 600 mg/day).
• Give it all at bedtime and titrate by 50 to 75 mg every few days to weekly, guided by sedation. Divided daytime dosing at these levels is usually intolerable.
• In practice, many patients cannot climb past about 150 to 200 mg without unacceptable daytime sedation, which is why trazodone monotherapy for depression so often stalls.

For Other Indications

Dose Adjustments and Special Populations

• Geriatric: start 25–50 mg QHS. Trazodone is one of the most-used hypnotics in older adults, but it is not risk-free: orthostatic hypotension, falls, and next-day sedation are the main concerns.
• Hepatic impairment: hepatically metabolized (CYP3A4); use lower doses and titrate cautiously, and remember strong 3A4 inhibitors raise levels.
• Renal impairment: use caution; no formal dose adjustment defined.
• Priapism: an idiosyncratic risk with no clear dose relationship, reported far more often with trazodone than with other antidepressants. Counsel every male patient that a prolonged (>4 hour) or painful erection is a medical emergency that can cause permanent damage.
• Pediatric: not FDA-approved.

Stopping and Switching

• Discontinuation: low hypnotic doses can usually be stopped without a formal taper (watch for rebound insomnia); taper antidepressant-range doses after prolonged use.
• MAOI washout: allow 14 days in each direction between trazodone and an MAOI.

Part 4: Monitoring

Trazodone is refreshingly low-maintenance. There are no routine serum levels or mandatory labs; monitoring is clinical.

At Each Follow-Up, Ask About and Check

• Next-day sedation / functional impairment: the most common reason to adjust timing or dose.
• Orthostatic symptoms: dizziness, lightheadedness on standing; recheck orthostatic BP early in titration and in the elderly.
• Priapism (men): ask directly; reinforce that a prolonged (over 4 hours) or painful erection is an emergency.
• Emergent dysphoria/anxiety: a new worsening of mood or anxiety, particularly after adding a CYP2D6 inhibitor or in an adolescent, may signal an mCPP surge rather than "trazodone made me depressed" (see Part 7).

ECG: repeat periodically in the higher-risk groups listed in Part 2 (age 65 or older, cardiac disease, CYP3A4 inhibitor co-prescription, electrolyte or hepatic/renal issues).

In dementia populations: track behavioral response and consider periodic MMSE. Trazodone doesn't help cognition; the MMSE is there to confirm it isn't contributing to decline and to document the target symptoms.

Part 5: Side Effects and How to Manage Them

Almost all of trazodone's problems are predictable consequences of its receptor pharmacology (H1 blockade for sedation, alpha-1 blockade for orthostasis and priapism), and almost all are managed by lowering the dose, moving it to bedtime, or slowing the titration.

Next-Day Sedation / Daytime Somnolence

The most common complaint (31% vs 16% placebo in the XR trials), as you'd expect from the H1 antagonism.

• Dose entirely at bedtime, as early in the evening as sleep timing allows.
• Lower the dose, or fine-tune between standard doses (37.5, 75 mg).
• If sedation persists and the patient needs a hypnotic, consider a shorter-acting agent (e.g., zaleplon) instead of pushing trazodone.

Orthostatic Hypotension, Dizziness, Syncope

Orthostasis, driven by alpha-1 blockade, is the most clinically important adverse effect. It matters most in the elderly, where it drives falls and fractures.

• Counsel on position changes: sit on the edge of the bed for a minute before standing; rise slowly; hold onto furniture when walking at night.
• Slow the titration and start low.
• Check orthostatic BP at baseline and early titration in at-risk patients.
• Refractory or severe cases: compression stockings or an abdominal binder; ensure adequate hydration.
• Syncope is rare but real; take it seriously in anyone with cardiac disease.

Priapism: Rare, Serious, Warn Everyone

Nausea

Nausea runs at roughly twice the placebo rate and is usually mild. Have the patient take the dose with food, and reassure them that it typically settles.

Headache

Can occur, and may relate to the mCPP metabolite (which is migraine-provoking). In a patient with an active migraine disorder, be cautious with trazodone and nefazodone, which are both metabolized to mCPP.

What Trazodone Doesn't Cause

Two advantages over most antidepressants earn it a place despite the sedation:

• Sexual dysfunction: minimal. A major advantage over SSRIs and SNRIs.
• Weight gain: minimal to none. Another major advantage, notably better than mirtazapine, its closest sedating-antidepressant cousin.

Part 6: Overdose and Toxicity

Trazodone has no boxed warning specific to the drug (it carries the standard antidepressant-class warning about suicidal ideation in patients under 25).

In overdose, trazodone is comparatively benign among antidepressants and far safer than the tricyclics. The picture is dominated by:

• Sedation and CNS depression
• Orthostatic hypotension
• Respiratory depression (dose-dependent; the serious risk)
• Priapism
• QT prolongation at high levels

Management is supportive (airway, fluids for hypotension, cardiac monitoring). There is no specific antidote.

QT Prolongation and Torsades

Trazodone prolongs the QT interval in a dose-dependent fashion, and the risk rises sharply when a CYP3A4 inhibitor pushes levels up, or when it is stacked with other QT-prolonging drugs (methadone, ziprasidone) or electrolyte derangement. Parts 2 and 4 set ECG thresholds for this reason. In an otherwise healthy patient at hypnotic doses, clinically meaningful QT effects are uncommon.

The Suicidality Signal

An observational VA cohort (about 350,000 veterans) found trazodone associated with a roughly 1.5 times higher rate of suicide attempts versus zolpidem. This is almost certainly confounding, not causation: trazodone is preferentially prescribed for nightmares and PTSD, populations with a higher baseline suicide risk, and the analysis didn't control for substance use, impulsivity, or drug interactions. There is no prospective evidence that trazodone causes suicidality, and the current data are insufficient to recommend against its use. Prescribe on the merits, and screen for suicidality as you would with any patient.

Part 7: Drug Interactions

Trazodone is a CYP3A4 substrate, and its active metabolite mCPP (m-chlorophenylpiperazine) is cleared by CYP2D6. Each fact produces a clinically important interaction, and these are the two that matter: learn them and you know trazodone's interactions.

1. CYP3A4 Inhibitors: Higher Trazodone Levels

• Culprits: ketoconazole and azole antifungals, ritonavir, clarithromycin/erythromycin, nefazodone, grapefruit; also relevant alongside QT-prolongers like methadone and ziprasidone.
• Effect: more sedation, morning grogginess, and increased QT prolongation/torsades risk.
• Action: reduce the trazodone dose; consider an ECG if the combination is necessary.

2. CYP2D6 Inhibitors: Higher mCPP Levels

This is the subtle one, and the one clinicians miss. mCPP is a 5-HT2C agonist, and an abrupt spike in its level is dysphorogenic, anxiogenic, and even hallucinogenic. Block CYP2D6 and mCPP accumulates.

• Culprits: fluoxetine, paroxetine, duloxetine, bupropion, sertraline at 150 mg/day or higher.
• What it looks like: a patient (classically an adolescent) develops new dysphoria, anxiety, or self-harm ideation after a 2D6 inhibitor is added. On paper it reads as "trazodone caused depression"; it's actually an mCPP surge.

3. MAOIs

Package labeling flags MAOIs, and standard teaching demands a 14-day washout. Counterintuitively, there is a well-established clinical exception: low-dose trazodone can be used safely with an MAOI as a sleep aid, and as a bridge. One expert group reported about 80 patients treated with trazodone on top of an MAOI safely and effectively, using it to cover the SSRI-washout gap while awaiting MAOI efficacy. It remains serotonergic, so use judgment, but the reflexive "never combine" is not correct for low sleep doses.

4. Other Serotonergic Drugs and CNS Depressants

• Serotonin syndrome risk is low with trazodone relative to other serotonergics, and it is rarely the culprit, but the risk is additive with SSRIs/SNRIs, triptans, linezolid, and the like. Monitor when stacking.
• CNS depressants (benzodiazepines, opioids, alcohol): additive sedation and respiratory depression (see Part 6). This is the interaction most likely to hurt someone.

Part 8: Special Populations

Elderly (65 and Older)

Trazodone demands the most respect in older adults, entirely because of orthostasis leading to falls and fractures.

• Start low (25 mg qhs is reasonable), titrate slowly.
• Counsel hard on slow position changes; assess fall risk before prescribing.
• Consider baseline/periodic ECG for QT.
• Upside: it remains useful and relatively safe for sleep in older adults and in dementia BPSD compared with the alternatives (antipsychotics, benzodiazepines, z-drugs), and it doesn't accumulate the way long-acting benzodiazepines do. A UK dementia cohort (mean age about 79) tolerated 50 to 300 mg/day acceptably for behavioral and sleep symptoms.
• Bottom line: excellent option for the robust older adult with insomnia; think twice in the frail faller.

Pregnancy

Former FDA Category C. Trazodone has a long history of use and no established pattern of major malformation, and is often considered relatively safe, but the human data remain sparse. Individualize, weigh against untreated maternal illness, and coordinate with obstetrics. For pregnancy-related insomnia in particular, non-pharmacologic measures come first.

Lactation

Data are limited. Small amounts pass into breast milk. If used, prefer the lowest effective dose, dose after the last evening feed, and monitor the infant for sedation, in coordination with pediatrics.

Renal Impairment

Trazodone is extensively metabolized, and less than 1% of an oral dose is excreted unchanged in the urine. The label states it has not been studied in renal impairment and should be used with caution in that population. Start low and monitor clinically. No specific dose-reduction table is well established.

Hepatic Impairment

Trazodone is hepatically metabolized (CYP3A4). Use caution in mild-to-moderate disease and avoid or minimize in severe hepatic impairment; reduced clearance raises levels and QT risk. (Its cousin nefazodone carries a true hepatotoxicity warning; trazodone does not, but impaired metabolism is still a reason to go low.)

Children and Adolescents

• No FDA pediatric depression indication; the class suicidality warning applies. Trazodone is used off-label mainly for sleep.
• The mCPP interaction is most dangerous here: adding a CYP2D6 inhibitor can precipitate dysphoria, anxiety, and self-harm ideation. If you use trazodone in an adolescent already on, or about to start, a 2D6 inhibitor, titrate carefully and monitor mood closely.

Part 9: Discontinuation

Discontinuation is the easy part. As a sedating antidepressant with modest serotonergic reuptake activity and a short half-life, trazodone has a low discontinuation-syndrome risk.

• After short-term or low-dose (hypnotic) use, it can generally be stopped without a formal taper.
• After chronic or higher-dose use, a brief taper over a week or two is reasonable for comfort, but a dramatic protocol is not required.
• Watch for rebound insomnia when stopping a nightly hypnotic: expected, transient, and best pre-empted by tapering the last stretch and reinforcing sleep hygiene rather than immediately re-dosing.

There is no rebound-mania phenomenon and no "loss of future response" concern of the kind that governs lithium discontinuation.

Part 10: Trazodone vs the Alternatives

As a Hypnotic

• vs benzodiazepines: trazodone is non-scheduled, non-addictive, and improves sleep architecture (increases slow-wave sleep) where benzodiazepines degrade it. Benzodiazepines have faster, more reliable hypnotic potency but carry dependence, tolerance, and cognitive/fall liabilities. Trazodone wins for chronic and comorbid insomnia.
• vs z-drugs (zolpidem, eszopiclone, zaleplon): far cheaper, non-scheduled, and free of the complex-sleep-behavior boxed warning, though the head-to-head trial had zolpidem ahead on efficacy at one week. The trade-off is more morning sedation. For most patients needing ongoing sleep help, trazodone is the more sensible long-term choice; z-drugs win when a clean, short, as-needed knockout is needed.
• vs ramelteon: ramelteon has no GABA activity and even less behavioral risk, but costs about $3/dose and is a weaker hypnotic; trazodone is preferred on cost and efficacy.
• vs low-dose doxepin (Silenor): for sleep, branded low-dose doxepin offers no clear advantage over generic trazodone at comparable effect.
• vs mirtazapine: similar sleep efficacy, both useful in dementia; trazodone causes less weight gain, while mirtazapine may be preferred when appetite stimulation is desirable.

As an Antidepressant

• Lower efficacy and higher dropout than most modern antidepressants in meta-analysis, but the dropouts are largely sedation-driven, and the drug's absence of weight gain and sexual dysfunction is a real edge for the right patient.
• Best positioned as a second/third-line agent, or as the antidepressant titrated up in a patient who is already taking it for sleep and needs mood coverage: one drug doing two jobs.

Mechanism

Trazodone is a SARI (serotonin antagonist and reuptake inhibitor), a triazolopyridine/phenylpiperazine compound. Its actions are strongly dose-dependent, which is why the same molecule is a hypnotic at 50 mg and an antidepressant at 300 mg:

• 5-HT2A (and 5-HT2C) antagonism: the dominant action at low doses; drives sleep improvement, improves sleep architecture, and underlies the anti-akathisia effect.
• Potent H1 (histamine) antagonism: sedation.
• Alpha-1 adrenergic antagonism: orthostatic hypotension and priapism.
• Serotonin reuptake inhibition: meaningful at the higher antidepressant doses; combined with 5-HT2A blockade, this is the antidepressant mechanism.
• 5-HT1A agonism: contributes to the antidepressant/anxiolytic effect.

The active metabolite mCPP (a 5-HT2C agonist, cleared by CYP2D6) is the pharmacological wildcard: dysphorogenic and anxiogenic when it spikes, which is the basis of the CYP2D6 interaction. Half-life is about 7 to 8 hours, long enough to maintain sleep across the night, short enough to usually clear by morning.

The Bedside Cheat Sheet

Also remember that trazodone improves sleep architecture, while benzos and z-drugs degrade it. QT is dose-dependent, which is why the ECG thresholds exist. Discontinuation is easy, with a short half-life, minimal withdrawal, and no rebound mania; just watch for transient rebound insomnia. It is not first-line for depression, but first-rate for insomnia, especially insomnia riding on depression, PTSD, or dementia.